Wall Street Zen Downgrades MEI Pharma (NASDAQ:LITS) to Sell

MEI Pharma (NASDAQ:LITS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

MEI Pharma Stock Up 3.3%

LITS stock opened at $2.80 on Friday. The company has a market cap of $91.95 million, a PE ratio of -0.59 and a beta of 0.38.

MEI Pharma Company Profile

MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.